培美曲塞联合长春瑞滨治疗老年中晚期非小细胞肺癌的临床观察  

Clinical research on pemetrexed combined with navelbine in the treatment of elderly patients with advanced non-small-cell lung cancer

作　　者：汪明云[1] 赵华头[1] 孙贵富[1] 曹友红[1] 

机构地区：[1]高淳县人民医院肿瘤科,江苏南京211300

出　　处：《中国肿瘤临床与康复》2010年第6期519-521,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的研究培美曲塞(Alimta)联合长春瑞滨(NVB)治疗老年中晚期非小细胞肺癌(NSCLC)的疗效及不良反应。方法入组33例老年中晚期非小细胞肺癌初治或复治患者,培美曲塞500mg/m2,静脉滴注10min以上,第1天;长春瑞滨25mg/m2,加生理盐水40ml静脉推注,第1、8天,每3周为一周期,2个周期后评价疗效。结果 33例患者中完全缓解(CR)1例,部分缓解(PR)17例,稳定(SD)9例,进展(PD)6例,有效率(CR+PR)54.5%。结论培美曲塞(Pemetrexed Alim-ta)联合长春瑞滨(Navelbine,NVB)治疗老年中晚期非小细胞肺癌(NSCLC)的疗效较好,副作用可耐受,可作为治疗老年中晚期非小细胞肺癌(NSCLC)的一线或二线化疗方案。Objective To observe the therapeutic effectiveness and toxicity of pemetrexed combined with navelbine（NVB） in the treatment of elderly patients with advanced non-small-cell lung cancer（NSCLC）.Methods Thirty-three patients with advanced NSCLC were treated with pemetrexed 500 mg/m2 iv infusion longer than 10 min d1 and NVB 25 mg/m2＋saline 40 ml iv bolus d1,8,the schedule was repeated every 3 weeks and the therapeutic effectiveness was evaluated after 2 cycles.Results The objective response could be evaluated in all cases.There were 1 case with CR,17 PR,9 SD and 6 PD,with response rate（CR＋PR）of 54.5%（18/33）.The common adverse effects were leucopenia,anemia and gastrointestinal reaction,etc.Conclusion The pemetrexed combined with NVB regimen is effective in the treatment of advanced NSCLC with good tolerence.It can be used as the first and second line chemotherapy.

关 键 词：培美曲塞 长春瑞滨 肺肿瘤/化学疗法 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]